Liang Jin-Xiao, Gao Wei, Zeng Xiao-Wei, Cheng Guo-Ping, Cai Lei, Tao Kai-Yi, Yang Xun
Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang 310000, P.R. China.
Oncol Lett. 2020 Nov;20(5):225. doi: 10.3892/ol.2020.12088. Epub 2020 Sep 11.
Small ubiquitin-like modifier 4 (SUMO4) is the latest member of the sumoylation family, which enhances the stability of protein, regulates the distribution and localization of the protein, and affects the transcription activity of the protein. However, the role of SUMO4 in non-small cell lung cancer (NSCLC) has not yet been reported. The present study first demonstrated that SUMO4 was upregulated in a number of tissues from patients with NSCLC. Immunohistochemistry was performed to demonstrate the expression level of SUMO4 in lung cancer tumor tissues. Following the transfection, The EMT status and signaling pathway activation regulated by SUMO4-siRNA was assessed by western blotting. The Transwell and wound healing assays were performed to investigate the regulatory effect of SUMO4-siRNA on cell migration and invasion. Cell Counting Kit-8 assay was performed to investigate whether SUMO4-siRNA affected the chemosensitivity of the NSCLC cells to cisplatin. Statistical analysis of immunohistochemical results from the tissues showed that the overexpression of SUMO4 was significantly associated with sex, tumor type, history of smoking, T stage and poor prognosis. It was also identified that SUMO4 small interfering RNA attenuated invasion and migration in NSCLC cell lines, as well chemosensitivity to cisplatin via the inhibition of the JAK2/STAT3 pathway. In conclusion, SUMO4 may play an important role in the poor prognosis of patients with NSCLC. The present study indicates that SUMO4 may be a potential therapeutic target for NSCLC.
小泛素样修饰因子4（SUMO4）是类泛素化修饰家族的最新成员，它可增强蛋白质的稳定性，调节蛋白质的分布和定位，并影响蛋白质的转录活性。然而，SUMO4在非小细胞肺癌（NSCLC）中的作用尚未见报道。本研究首次证明SUMO4在NSCLC患者的多种组织中表达上调。采用免疫组织化学法检测肺癌肿瘤组织中SUMO4的表达水平。转染后，通过蛋白质印迹法评估SUMO4-siRNA对上皮-间质转化（EMT）状态和信号通路激活的调控作用。采用Transwell实验和伤口愈合实验研究SUMO4-siRNA对细胞迁移和侵袭的调控作用。采用细胞计数试剂盒-8实验研究SUMO4-siRNA是否影响NSCLC细胞对顺铂的化疗敏感性。对组织免疫组化结果进行统计分析显示，SUMO4的过表达与性别、肿瘤类型、吸烟史、T分期及预后不良显著相关。研究还发现，SUMO4小干扰RNA可通过抑制JAK2/STAT3信号通路减弱NSCLC细胞系的侵袭和迁移能力以及对顺铂的化疗敏感性。总之，SUMO4可能在NSCLC患者的不良预后中起重要作用。本研究表明SUMO4可能是NSCLC的一个潜在治疗靶点。
